The Concerns Regarding Invokana Related Complications

by Terry Bryant

More research will have to be done on the drug, but there are already serious concerns regarding Invokana related complications. The fight against type 2 diabetes is ramping up in the U.S., and more treatments are needed to deal with it effectively. Until recently, these treatments have relied on boosting the concentration of insulin in the blood, but canagliflozin takes a different approach. Instead of increasing insulin, it reduces blood sugar by forcing the body to excrete it in urine. It’s an approach with proven effectiveness, but the early results show there may be troubling health concerns under the surface.

Specifically, canagliflozin can cause a condition known as diabetic ketoacidosis (DKA). DKA is considered the most severe of concerns among Invokana related complications, as it can kill if left untreated. DKA is caused by a drop in insulin levels, which itself can be caused by urinary tract infections or dehydration, both of which are noted concerns associated with the drug. Once insulin levels drop, the body can no longer metabolize blood glucose effectively, forcing the body to use fat instead. This releases waste materials known as ketones into the blood, and their natural acidity raises the acid level of the blood. This leads to nausea, vomiting, and eventually coma or death via brain edema.

So far, the FDA has recognized more than 20 adverse events associated with canagliflozin. As time goes on, there will likely be more cases, so patients using the drug should consult with a doctor if they experience a sudden change in their well-being, as it may signal DKA.